¿ Aclara BioSciences Inc., of Mountain View, Calif., entered an exclusive license agreement with Zeptosens AG, of Witterswil, Switzerland, for access to microfluidics intellectual property similar to the property under dispute with Caliper Technologies Corp., of Mountain View, Calif. Financial terms were undisclosed.
¿ Amylin Pharmaceuticals Inc., of San Diego, initiated a Phase II study of its diabetes candidate AC2993 (exendin-4) in glucose control in more than 100 patients with Type II diabetes. The 28-day, placebo-controlled, randomized, multicenter study is designed to evaluate the addition of AC2993 to patients' oral therapies compared to oral therapy alone.
¿ Applied Biosystems Inc., of Foster City, Calif., said deCode Genetics Inc., of Reykjavik, Iceland, purchased 50 ABI PRISM 3700 DNA Analyzers for ultra-high-throughput, short-tandem repeat genotyping to determine genetic factors that influence human disease. The acquisition is expected to increase deCode's average genotyping throughput nearly fivefold to about 12 million genotypes per month.
¿ Calypte Biomedical Corp., of Alameda, Calif., said it secured an equity line facility through Landenburg Thalmann & Co. Inc. giving the company the option to obtain as much as $25 million through the issuance of common stock to a private investment fund in a series of draw- downs over a 12-month period. Calypte said it will use the proceeds to fund new product development.
¿ ChemBridge Corp., of San Diego, agreed to provide Bristol-Myers Squibb Co., of New York, non-exclusive access to its PHARMACore combinatorial lead discovery library. Financial terms were undisclosed.
¿ Cistron Biotechnology Inc., of Parsippany, N.J., approved the proposed merger with a subsidiary of Celltech Group plc, of Slough, England. Cistron shareholders will receive an American Depository Share for each share of Cistron. The transaction is expected to close this week.
¿ Curis Inc., of Cambridge, Mass., presented findings at the Fifth Annual Diabetic Neuropathy Satellite Meeting of the Society for Diabetic Neuropathy showing that treatment with the Sonic Hedgehog protein restored nerve function to normal in preclinical models of diabetic neuropathy. Data from preclinical models showed complete restoration of both sensory and motor nerve function after five weeks of treatment .
¿ DepoMed Inc., of Menlo Park, Calif., said OrbiMed Advisors LLC purchased 50 units, each consisting of 28,571 shares and four-year warrants for the purchase of 7,571 shares at $5.50 per share, for a total of $5 million. DepoMed will use the funds to speed product development focused on its proprietary gastric retention drug delivery platform.
¿ Epic Therapeutics Inc., of Norwood, Mass., said it has successfully produced protein microspheres from insulin in the optimal size range for pulmonary delivery. The microspheres were created using Epic's ProMaxx formulation system.
¿ Medicure Inc., of Winnipeg, Manitoba, agreed to acquire the option to license three cardiovascular therapeutics from George Washington University, of Washington. The agreement allows Medicure to evaluate and license the therapeutics, and to acquire exclusive worldwide rights to the technology in exchange for royalties and other commercialization-contingent payments.